Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	25.18	41.92	45.2	100.44	178.87	131.33
Short-Term Investments	-	-	35.8	177.19	197.68	510.09
Cash & Short-Term Investments	25.18	41.92	81	277.63	376.55	641.42
Cash Growth	-53.73%	-48.25%	-70.82%	-26.27%	-41.30%	76.96%
Accounts Receivable	0.37	0.53	0.92	3.68	6.01	5.22
Other Receivables	4.24	4.07	3.14	0.79	0.35	1.04
Receivables	4.61	4.6	4.07	4.47	6.36	6.26
Prepaid Expenses	7.81	5.18	9.26	18.22	15.86	11.99
Total Current Assets	37.6	51.69	94.33	300.33	398.77	659.67
Property, Plant & Equipment	32.84	34.76	52.87	125.53	124.7	112.37
Long-Term Investments	-	-	-	29.85	88.17	50.53
Goodwill	-	-	-	37.55	39.7	42.8
Other Intangible Assets	-	-	-	50.73	53.76	58.13
Long-Term Deferred Tax Assets	-	-	-	1.12	1.06	0.47
Other Long-Term Assets	15.73	15.19	18.13	17.41	15.76	14.58
Total Assets	86.17	101.64	165.32	562.51	721.92	938.55
Accounts Payable	18.2	15.49	15.26	22.42	9.76	12.55
Accrued Expenses	23.8	17.56	16.15	33.39	28.39	30.66
Current Portion of Leases	-	4.31	4.59	4.12	4.03	3.69
Current Unearned Revenue	7.56	7.56	-	51.78	85.71	91.64
Other Current Liabilities	-	0.9	11.73	-	-	5
Total Current Liabilities	49.56	45.81	47.73	111.71	127.89	143.55
Long-Term Leases	24.88	26.25	33.52	38.99	44.06	38.4
Long-Term Unearned Revenue	5.87	5.87	-	109.38	166.78	245.05
Long-Term Deferred Tax Liabilities	0.02	-	-	6.27	6.65	7.19
Other Long-Term Liabilities	0.93	0.93	1.19	1.21	1.22	7.01
Total Liabilities	81.26	78.87	82.43	267.55	346.58	441.18
Common Stock	2.25	2.13	1.78	1.67	1.46	1.42
Additional Paid-In Capital	1,543	1,532	1,492	1,450	1,334	1,269
Retained Earnings	-1,535	-1,504	-1,406	-1,149	-956.27	-777.98
Comprehensive Income & Other	-5.53	-7.53	-4.6	-8.4	-3.99	5.42
Total Common Equity	4.91	22.77	82.89	294.96	375.34	498.23
Minority Interest	-	-	-	-	-	-0.87
Shareholders' Equity	4.91	22.77	82.89	294.96	375.34	497.37
Total Liabilities & Equity	86.17	101.64	165.32	562.51	721.92	938.55
Total Debt	24.88	30.57	38.1	43.11	48.08	42.09
Net Cash (Debt)	0.3	11.35	42.9	264.37	416.64	649.87
Net Cash Growth	-98.71%	-73.54%	-83.77%	-36.55%	-35.89%	91.19%
Net Cash Per Share	0.00	0.06	0.25	1.71	2.88	4.83
Filing Date Shares Outstanding	233.17	224.71	178.91	168.48	145.97	143.25
Total Common Shares Outstanding	233.17	212.84	178.13	166.79	145.92	142.06
Working Capital	-11.97	5.89	46.6	188.62	270.88	516.12
Book Value Per Share	0.02	0.11	0.47	1.77	2.57	3.51
Tangible Book Value	4.91	22.77	82.89	206.68	281.88	397.31
Tangible Book Value Per Share	0.02	0.11	0.47	1.24	1.93	2.80
Machinery	-	32.78	47.02	54.72	49.85	30.7
Construction In Progress	-	-	1.09	14.77	4.73	12.09
Leasehold Improvements	-	24.92	29.81	30.57	21.97	15.95

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q